Life-Threatening Complications Continue to Challenge Venous Access.
Blood platelets react to the catheter material, forming blood clots that impede catheter flow and can lead to serious conditions like deep vein thrombosis and pulmonary embolism.
Bacteria are introduced during catheter insertion or accumulate in thrombosed sections of the catheter wall, leading to bloodstream infections.
Catheters can damage the vein wall during insertion, leading to swelling and pain.
Our Novel Catheter Material Could Change Everything.
Testing includes an FDA-recognized blood flow loop test conducted by Thrombodine Inc and placement of HydroPICC devices in ovine models for 14 or 28 days. PowerPICC and BioFlo are registered trademarks of Bard Access Systems and AngioDynamics, respectively.
A Suite of Venous Access Devices
Access Vascular plans to develop a variety of venous catheters leveraging our novel hydrogel material that address the $3 billion global venous access market